Funding · Healthcare & Life Sciences

Gabify raises over ₹1 crore for autism screening

What they do

Gabify builds an AI-led ecosystem to screen and support children with autism and ADHD

It raised over ₹1 crore from IP Ventures and Government of India initiatives

The platform has achieved over 90% reliability and is validated with AIIMS and ICMR

Gabify has raised over ₹1 crore in funding from IP Ventures and Government of India initiatives.
The company builds an AI-led early intervention ecosystem for developmental conditions like autism and ADHD.
Its product Neurolens screens children using speech and behavior data.
Another product, Connect, boosts therapist productivity.
Gabify delivers developmental screening insights instantly, complementing human expertise.
The platform is designed to work in low-connectivity environments for use in anganwadis, schools, and rural communities.
Gabify aims to screen over one million children in the next 5–10 years.

Gabify has achieved over 90% reliability in developmental screening outcomes.
It has been validated with institutions like AIIMS and ICMR through comparative studies.
The company started as a small bootstrapped team with interns, focusing on clinical strength before scaling.
Gabify's vision is to become India's first assistive health-tech unicorn.

Gabify builds an AI-led ecosystem for early intervention in developmental conditions like autism and ADHD.
Its product Neurolens screens via speech and behavior data.
Its product Connect boosts therapist productivity.
Gabify delivers developmental screening insights instantly, complementing human expertise.
The platform works in low-connectivity environments for screenings in anganwadis, schools, and rural communities.
Gabify has achieved over 90% reliability in developmental screening outcomes.

Gabify is collaborating with institutions aligned with India's National Education Policy for routine early screening.
It aims to screen over one million children in the next 5–10 years.
Gabify's vision is to become India's first assistive health-tech unicorn.

Product: AI-powered voice and vision analysis platform for early screening and therapy of autism, ADHD, and speech disorders
Customers: Preschools, schools, parents, and healthcare providers addressing neurodevelopmental disorder detection
How it makes money: B2B2C and B2C platform for clinical validation and therapy management
What sets it apart: Dual AI system combining voice and vision analysis with human-in-the-loop approach for clinical validation